<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font6" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font7" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font8" size="8" family="SymbolMT" color="#000000"/>
<text top="42" left="315" width="241" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/8/6/R66<b>Available online</b></text>
<text top="758" left="511" width="45" height="7" font="font2" id="p1_t2" reading_order_no="112" segment_no="17" tag_type="text">Page 5 of 12</text>
<text top="769" left="436" width="120" height="6" font="font3" id="p1_t3" reading_order_no="113" segment_no="18" tag_type="text">(page number not for citation purposes)</text>
<text top="367" left="57" width="240" height="9" font="font4" id="p1_t4" reading_order_no="31" segment_no="9" tag_type="text">have class II p53 mutations, which have been postulated to be<i>(page number not for citation purposes)</i></text>
<text top="379" left="57" width="211" height="9" font="font4" id="p1_t5" reading_order_no="32" segment_no="9" tag_type="text">associated with defects in spindle checkpoint control.</text>
<text top="402" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="33" segment_no="11" tag_type="text">Because not all mutations in p53 lead to IHC evidence of p53</text>
<text top="414" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="34" segment_no="11" tag_type="text">over-expression, we assessed the sensitivity and specificity of</text>
<text top="426" left="57" width="240" height="9" font="font4" id="p1_t8" reading_order_no="35" segment_no="11" tag_type="text">IHC for detecting p53 mutations that had been identified by</text>
<text top="438" left="57" width="240" height="9" font="font4" id="p1_t9" reading_order_no="36" segment_no="11" tag_type="text">sequencing. We found that IHC had a sensitivity of 63% and</text>
<text top="449" left="57" width="240" height="9" font="font4" id="p1_t10" reading_order_no="37" segment_no="11" tag_type="text">a specificity of 73%. Because previous studies have shown</text>
<text top="461" left="57" width="240" height="9" font="font4" id="p1_t11" reading_order_no="38" segment_no="11" tag_type="text">that over-expression of p53 is highly correlated with missense</text>
<text top="473" left="57" width="240" height="9" font="font4" id="p1_t12" reading_order_no="39" segment_no="11" tag_type="text">mutations [39], we evaluated the level of agreement between</text>
<text top="485" left="57" width="240" height="9" font="font4" id="p1_t13" reading_order_no="40" segment_no="11" tag_type="text">IHC evidence of p53 over-expression and the presence of a<a href="">mutations [39], we </a>evaluated the level of agreement between</text>
<text top="496" left="57" width="240" height="9" font="font4" id="p1_t14" reading_order_no="41" segment_no="11" tag_type="text">missense mutation in p53. IHC detected the majority of mis-</text>
<text top="508" left="57" width="240" height="9" font="font4" id="p1_t15" reading_order_no="42" segment_no="11" tag_type="text">sense mutations identified by sequence analysis, with a sensi-</text>
<text top="520" left="57" width="240" height="9" font="font4" id="p1_t16" reading_order_no="43" segment_no="11" tag_type="text">tivity of 90%. However, the specificity was 72%, reflecting the</text>
<text top="532" left="57" width="240" height="9" font="font4" id="p1_t17" reading_order_no="44" segment_no="11" tag_type="text">fact that not all mutations detected by sequencing were</text>
<text top="543" left="57" width="67" height="9" font="font4" id="p1_t18" reading_order_no="45" segment_no="11" tag_type="text">detected by IHC.</text>
<text top="85" left="315" width="86" height="8" font="font5" id="p1_t19" reading_order_no="46" segment_no="1" tag_type="title">Treatment response</text>
<text top="97" left="315" width="240" height="9" font="font4" id="p1_t20" reading_order_no="47" segment_no="3" tag_type="text">The rate of response to paclitaxel did not differ significantly on<b>Treatment response</b></text>
<text top="109" left="315" width="240" height="9" font="font4" id="p1_t21" reading_order_no="48" segment_no="3" tag_type="text">the basis of HER2 or p53 status (Table 4). The response rate</text>
<text top="120" left="315" width="240" height="9" font="font4" id="p1_t22" reading_order_no="49" segment_no="3" tag_type="text">was 23% among women with HER2-positive tumors and 24%<a href=""> (Table 4). Th</a>e response rate</text>
<text top="132" left="315" width="241" height="9" font="font4" id="p1_t23" reading_order_no="50" segment_no="3" tag_type="text">among those with HER2-negative tumors ( P = 0.96); the</text>
<text top="144" left="315" width="240" height="9" font="font4" id="p1_t24" reading_order_no="51" segment_no="3" tag_type="text">respective response rates for tumors with and for those with-</text>
<text top="156" left="315" width="241" height="9" font="font4" id="p1_t25" reading_order_no="52" segment_no="3" tag_type="text">out p53 over-expression were 23% and 21% ( P = 0.79).<i>P </i></text>
<text top="167" left="315" width="240" height="9" font="font4" id="p1_t26" reading_order_no="53" segment_no="3" tag_type="text">Lower response rates were observed in patients aged 50</text>
<text top="179" left="315" width="240" height="9" font="font4" id="p1_t27" reading_order_no="54" segment_no="3" tag_type="text">years or less (14% versus 29%) and a HER2 score of 0 to 1+</text>
<text top="191" left="315" width="241" height="9" font="font4" id="p1_t28" reading_order_no="55" segment_no="3" tag_type="text">(18% versus 35%); however, only age was significantly asso-</text>
<text top="203" left="315" width="240" height="9" font="font4" id="p1_t29" reading_order_no="56" segment_no="3" tag_type="text">ciated with TTF ( P = 0.045) after adjustment for ER/PR status<i>P </i></text>
<text top="214" left="315" width="107" height="9" font="font4" id="p1_t30" reading_order_no="57" segment_no="3" tag_type="text">and HER2 status (Table 5).</text>
<text top="238" left="315" width="44" height="8" font="font5" id="p1_t31" reading_order_no="58" segment_no="6" tag_type="title">Outcomes</text>
<text top="250" left="315" width="240" height="9" font="font4" id="p1_t32" reading_order_no="59" segment_no="7" tag_type="text">There was no meaningful difference in TTF between tumors</text>
<text top="261" left="315" width="240" height="9" font="font4" id="p1_t33" reading_order_no="60" segment_no="7" tag_type="text">with and without p53 over-expression (median time: 4.0</text>
<text top="273" left="315" width="241" height="9" font="font4" id="p1_t34" reading_order_no="61" segment_no="7" tag_type="text">months versus 4.4 months; P = 0.061); however, OS was sig-</text>
<text top="285" left="315" width="240" height="9" font="font4" id="p1_t35" reading_order_no="62" segment_no="7" tag_type="text">nificantly reduced in this group of patients (11.5 months ver-<i>P </i></text>
<text top="297" left="315" width="241" height="9" font="font4" id="p1_t36" reading_order_no="63" segment_no="7" tag_type="text">sus 14.4 months; P = 0.002; Figure 1). There was a trend</text>
<text top="308" left="315" width="241" height="9" font="font4" id="p1_t37" reading_order_no="64" segment_no="7" tag_type="text">toward a shorter TTF among patients who were HER2 positive<a href="">and HER2 status (Table 5).</a></text>
<text top="320" left="315" width="240" height="9" font="font4" id="p1_t38" reading_order_no="65" segment_no="7" tag_type="text">than among those who were HER negative (2.3 months versus<b>Outcomes</b></text>
<text top="332" left="315" width="241" height="9" font="font4" id="p1_t39" reading_order_no="66" segment_no="7" tag_type="text">4.2 months; P = 0.067), but HER2 status was not associated</text>
<text top="344" left="315" width="215" height="9" font="font4" id="p1_t40" reading_order_no="67" segment_no="7" tag_type="text">with statistically significant differences in OS (Table 6).</text>
<text top="367" left="315" width="241" height="9" font="font4" id="p1_t41" reading_order_no="68" segment_no="10" tag_type="text">Although TTF did not differ by ER status ( P = 0.13) in the</text>
<text top="379" left="315" width="240" height="9" font="font4" id="p1_t42" reading_order_no="69" segment_no="10" tag_type="text">biomarker subset, OS was significantly better in this group of<i>P </i></text>
<text top="391" left="315" width="241" height="9" font="font4" id="p1_t43" reading_order_no="70" segment_no="10" tag_type="text">ER-positive tumors ( P = 0.003). This observation was also</text>
<text top="402" left="315" width="241" height="9" font="font4" id="p1_t44" reading_order_no="71" segment_no="10" tag_type="text">true of ER status in the entire cohort of patients from CALGB</text>
<text top="414" left="315" width="241" height="9" font="font4" id="p1_t45" reading_order_no="72" segment_no="10" tag_type="text">9342, in which TTF did not differ by ER status ( P = 0.27),</text>
<text top="426" left="315" width="240" height="9" font="font4" id="p1_t46" reading_order_no="73" segment_no="10" tag_type="text">whereas ER positivity was associated with more favorable OS<i>P </i></text>
<text top="438" left="315" width="55" height="9" font="font4" id="p1_t47" reading_order_no="74" segment_no="10" tag_type="text">( P = 0.0003).<a href=""> 0.002; Figure 1)</a>. There was a trend</text>
<text top="461" left="315" width="240" height="9" font="font4" id="p1_t48" reading_order_no="75" segment_no="12" tag_type="text">To determine whether particular p53 mutations predicted a</text>
<text top="473" left="315" width="240" height="9" font="font4" id="p1_t49" reading_order_no="76" segment_no="12" tag_type="text">worse outcome, we grouped missense mutations into nono-</text>
<text top="485" left="315" width="240" height="9" font="font4" id="p1_t50" reading_order_no="77" segment_no="12" tag_type="text">verlapping categories, according to the methodology of Alsner</text>
<text top="496" left="315" width="240" height="9" font="font4" id="p1_t51" reading_order_no="78" segment_no="12" tag_type="text">and coworkers [24]. However, the number of patients in each<i>P </i></text>
<text top="508" left="315" width="240" height="9" font="font4" id="p1_t52" reading_order_no="79" segment_no="12" tag_type="text">subgroup was too small to make meaningful comparisons</text>
<text top="520" left="315" width="240" height="9" font="font4" id="p1_t53" reading_order_no="80" segment_no="12" tag_type="text">(nine with mutations in direct DNA contact or zinc binding<a href="">6).</a></text>
<text top="532" left="315" width="240" height="9" font="font4" id="p1_t54" reading_order_no="81" segment_no="12" tag_type="text">residues, 10 with mutations in conserved domains, and 18</text>
<text top="543" left="315" width="172" height="9" font="font4" id="p1_t55" reading_order_no="82" segment_no="12" tag_type="text">with mutations outside conserved domains).<i>P </i></text>
<text top="85" left="57" width="28" height="7" font="font0" id="p1_t56" reading_order_no="1" segment_no="2" tag_type="title">Table 2</text>
<text top="104" left="57" width="189" height="7" font="font0" id="p1_t57" reading_order_no="2" segment_no="4" tag_type="text">Results of HER2 Immunohistochemistry and FISH</text>
<text top="123" left="61" width="20" height="7" font="font2" id="p1_t58" reading_order_no="3" segment_no="5" tag_type="table">Assay</text>
<text top="123" left="181" width="54" height="7" font="font2" id="p1_t59" reading_order_no="4" segment_no="5" tag_type="table">Patients ( n [%])<i>P </i></text>
<text top="139" left="61" width="65" height="7" font="font2" id="p1_t60" reading_order_no="5" segment_no="5" tag_type="table">HER2 CB11 score</text>
<text top="154" left="71" width="30" height="7" font="font2" id="p1_t61" reading_order_no="6" segment_no="5" tag_type="table">Negative</text>
<text top="154" left="181" width="38" height="7" font="font2" id="p1_t62" reading_order_no="7" segment_no="5" tag_type="table">130 (80%)</text>
<text top="170" left="71" width="26" height="7" font="font2" id="p1_t63" reading_order_no="8" segment_no="5" tag_type="table">Positive<i>P </i></text>
<text top="170" left="181" width="33" height="7" font="font2" id="p1_t64" reading_order_no="9" segment_no="5" tag_type="table">32 (20%)</text>
<text top="185" left="71" width="17" height="7" font="font2" id="p1_t65" reading_order_no="10" segment_no="5" tag_type="table">Total</text>
<text top="185" left="181" width="42" height="7" font="font2" id="p1_t66" reading_order_no="11" segment_no="5" tag_type="table">162 (100%)</text>
<text top="201" left="61" width="84" height="7" font="font2" id="p1_t67" reading_order_no="12" segment_no="5" tag_type="table">HER2 HercepTest score<i>P </i></text>
<text top="216" left="71" width="5" height="7" font="font2" id="p1_t68" reading_order_no="13" segment_no="5" tag_type="table">0</text>
<text top="216" left="181" width="33" height="7" font="font2" id="p1_t69" reading_order_no="14" segment_no="5" tag_type="table">63 (40%)</text>
<text top="232" left="71" width="5" height="7" font="font2" id="p1_t70" reading_order_no="15" segment_no="5" tag_type="table">1</text>
<text top="232" left="181" width="33" height="7" font="font2" id="p1_t71" reading_order_no="16" segment_no="5" tag_type="table">45 (28%)</text>
<text top="247" left="71" width="5" height="7" font="font2" id="p1_t72" reading_order_no="17" segment_no="5" tag_type="table">2<a href="">d coworkers [24]. Howe</a>ver, the number of patients in each</text>
<text top="247" left="181" width="33" height="7" font="font2" id="p1_t73" reading_order_no="18" segment_no="5" tag_type="table">17 (11%)</text>
<text top="263" left="71" width="5" height="7" font="font2" id="p1_t74" reading_order_no="19" segment_no="5" tag_type="table">3</text>
<text top="263" left="181" width="33" height="7" font="font2" id="p1_t75" reading_order_no="20" segment_no="5" tag_type="table">33 (21%)</text>
<text top="278" left="71" width="17" height="7" font="font2" id="p1_t76" reading_order_no="21" segment_no="5" tag_type="table">Total</text>
<text top="278" left="181" width="42" height="7" font="font2" id="p1_t77" reading_order_no="22" segment_no="5" tag_type="table">158 (100%)<b>Table 2</b></text>
<text top="294" left="61" width="40" height="7" font="font2" id="p1_t78" reading_order_no="23" segment_no="5" tag_type="table">HER2 FISH<b>Results of HER2 Immunohistochemistry and FISH</b></text>
<text top="309" left="71" width="84" height="7" font="font2" id="p1_t79" reading_order_no="24" segment_no="5" tag_type="table">HER2/CEP17 ratio &lt;2.0</text>
<text top="309" left="181" width="38" height="7" font="font2" id="p1_t80" reading_order_no="25" segment_no="5" tag_type="table">113 (74%)</text>
<text top="323" left="71" width="83" height="10" font="font2" id="p1_t81" reading_order_no="26" segment_no="5" tag_type="table">HER2/CEP17 ratio ≥ 2.0<i>n </i></text>
<text top="325" left="181" width="33" height="7" font="font2" id="p1_t82" reading_order_no="27" segment_no="5" tag_type="table">39 (26%)</text>
<text top="340" left="71" width="17" height="7" font="font2" id="p1_t83" reading_order_no="28" segment_no="5" tag_type="table">Total</text>
<text top="340" left="181" width="42" height="7" font="font2" id="p1_t84" reading_order_no="29" segment_no="5" tag_type="table">152 (100%)</text>
<text top="357" left="61" width="128" height="7" font="font2" id="p1_t85" reading_order_no="30" segment_no="8" tag_type="text">FISH, fluorescent in situ hybridization.</text>
<text top="567" left="57" width="28" height="7" font="font0" id="p1_t86" reading_order_no="83" segment_no="13" tag_type="title">Table 3</text>
<text top="586" left="57" width="186" height="7" font="font0" id="p1_t87" reading_order_no="84" segment_no="14" tag_type="text">Agreement among methods for measuring HER2</text>
<text top="605" left="61" width="26" height="7" font="font2" id="p1_t88" reading_order_no="85" segment_no="15" tag_type="table">Method</text>
<text top="605" left="283" width="51" height="7" font="font2" id="p1_t89" reading_order_no="86" segment_no="15" tag_type="table">Cohen's kappa</text>
<text top="605" left="405" width="34" height="7" font="font2" id="p1_t90" reading_order_no="87" segment_no="15" tag_type="table">Sensitivity</text>
<text top="605" left="481" width="35" height="7" font="font2" id="p1_t91" reading_order_no="88" segment_no="15" tag_type="table">Specificity</text>
<text top="621" left="61" width="64" height="7" font="font2" id="p1_t92" reading_order_no="89" segment_no="15" tag_type="table">FISH versus CB11</text>
<text top="621" left="283" width="61" height="7" font="font2" id="p1_t93" reading_order_no="90" segment_no="15" tag_type="table">83.0% (SE 5.3%)</text>
<text top="621" left="405" width="16" height="7" font="font2" id="p1_t94" reading_order_no="91" segment_no="15" tag_type="table">97%</text>
<text top="621" left="481" width="16" height="7" font="font2" id="p1_t95" reading_order_no="92" segment_no="15" tag_type="table">93%</text>
<text top="636" left="61" width="84" height="7" font="font2" id="p1_t96" reading_order_no="93" segment_no="15" tag_type="table">HercepTest versus FISH</text>
<text top="652" left="71" width="103" height="7" font="font2" id="p1_t97" reading_order_no="94" segment_no="15" tag_type="table">(0–1 versus 2–3) versus FISH</text>
<text top="652" left="283" width="61" height="7" font="font2" id="p1_t98" reading_order_no="95" segment_no="15" tag_type="table">72.0% (SE 6.2%)</text>
<text top="652" left="405" width="16" height="7" font="font2" id="p1_t99" reading_order_no="96" segment_no="15" tag_type="table">92%</text>
<text top="652" left="481" width="16" height="7" font="font2" id="p1_t100" reading_order_no="97" segment_no="15" tag_type="table">87%</text>
<text top="667" left="71" width="94" height="7" font="font2" id="p1_t101" reading_order_no="98" segment_no="15" tag_type="table">(0–2 versus 3) versus FISH</text>
<text top="667" left="283" width="61" height="7" font="font2" id="p1_t102" reading_order_no="99" segment_no="15" tag_type="table">79.2% (SE 6.0%)</text>
<text top="667" left="405" width="16" height="7" font="font2" id="p1_t103" reading_order_no="100" segment_no="15" tag_type="table">78%</text>
<text top="667" left="481" width="16" height="7" font="font2" id="p1_t104" reading_order_no="101" segment_no="15" tag_type="table">97%</text>
<text top="683" left="61" width="87" height="7" font="font2" id="p1_t105" reading_order_no="102" segment_no="15" tag_type="table">HercepTest versus CB11</text>
<text top="698" left="71" width="106" height="7" font="font2" id="p1_t106" reading_order_no="103" segment_no="15" tag_type="table">(0–1 versus 2–3) versus CB11</text>
<text top="698" left="283" width="61" height="7" font="font2" id="p1_t107" reading_order_no="104" segment_no="15" tag_type="table">70.0% (SE 6.3%)</text>
<text top="698" left="405" width="21" height="7" font="font2" id="p1_t108" reading_order_no="105" segment_no="15" tag_type="table">100%</text>
<text top="698" left="481" width="16" height="7" font="font2" id="p1_t109" reading_order_no="106" segment_no="15" tag_type="table">85%</text>
<text top="714" left="71" width="97" height="7" font="font2" id="p1_t110" reading_order_no="107" segment_no="15" tag_type="table">(0–2 versus 3) versus CB11</text>
<text top="714" left="283" width="61" height="7" font="font2" id="p1_t111" reading_order_no="108" segment_no="15" tag_type="table">84.2% (SE 5.4%)<i>in situ </i></text>
<text top="714" left="405" width="16" height="7" font="font2" id="p1_t112" reading_order_no="109" segment_no="15" tag_type="table">90%</text>
<text top="714" left="481" width="16" height="7" font="font2" id="p1_t113" reading_order_no="110" segment_no="15" tag_type="table">96%<b>Table 3</b></text>
<text top="730" left="61" width="259" height="7" font="font2" id="p1_t114" reading_order_no="111" segment_no="16" tag_type="text">FISH, fluorescent in situ hybridization; SE, standard error for Cohen's kappa.<b>Agreement among methods for measuring HER2</b></text>
</page>
</pdf2xml>
